Skip to main content
SpringerLink
Log in

Vascular Endothelial Growth Factor (VEGF) Bevacizumab and Hypertension

  • Chapter
  • First Online:
Clinical Cases in Cardio-Oncology

Part of the book series: Clinical Cases in Cardiology ((CCC))

  • 310 Accesses

Abstract

A 62-year-old male, with rectosigmoid cancer and peritoneal carcinomatosis, on FOLFIRI (Fluorouracil, Calcium Leucovorin, Citrovorum Factor, Folinic Acid) chemotherapy plus bevacizumab referred for treatment of hypertension (HTN). On examination he had blood pressure of 170/100 mmHg. He was started on ramipril, 5 mg/day, and blood pressure Holter monitor ordered. It showed average daytime blood pressure of 165/100 mmHg. Dose of ramipril increased to 10 mg/day. On further follow up, his blood pressure still was not well controlled. He was started on combination of chlorthalidone 25 mg/day and amlodipine 10 mg/day. After this, he had marginal improvement in his blood pressure.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mir O, Coriat R, Cabanes L, et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist. 2011;16(9):1325–32. https://doi.org/10.1634/theoncologist.2010-0002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol. 2006;24(9):1329–31. https://doi.org/10.1200/JCO.2005.04.5740.

    Article  PubMed  Google Scholar 

  3. Shah SR, Gressett Ussery SM, Dowell JE, et al. Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension. Ann Oncol. 2013;24(4):960–5. https://doi.org/10.1093/annonc/mds593.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Northern Ontario School of Medicine, Thunder Bay, ON, Canada

    Atooshe Rohani

Authors
  1. Atooshe Rohani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atooshe Rohani .

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rohani, A. (2021). Vascular Endothelial Growth Factor (VEGF) Bevacizumab and Hypertension. In: Clinical Cases in Cardio-Oncology. Clinical Cases in Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-71155-9_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-71155-9_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-71154-2

  • Online ISBN: 978-3-030-71155-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation